Use of antithrobomic agents in pregnancy and lactation: from the viewpoint of the cardiologist/rheumatologist (literature review)
https://doi.org/10.21518/2079-701X-2018-6-19-25
Abstract
The review focuses on the main aspects of the use of antithrombotic agents in women during pregnancy and lactation. It summarises the reasons for frequent development of gestational hypercoagulable state, which provokes some obstetric complications (preeclampsia, etc.) and increases the possibility of the occurrence of serious clinical situations such as lower extremity deep vein thrombosis and pulmonary embolism, thrombotic/thromboembolic complications in thrombophilia and antiphospholipid syndrome of various genesis, as well as prosthetic heart valves. It provides a brief description of antithrombotic agent groups and advanced approaches to the selection of antithrombotic agents in pregnant and lactating women. This article discusses in details individual clinical situations during which the agents under discussion may be used during pregnancy and lactation (prevention of preeclampsia, treatment of thrombotic and thromboembolic complications, prophylaxis of the latter, if patients are required to be on bed rest for more than 24 hours, planning for caesarean section and epidural anaesthesia, and in thrombophilia, antiphospholipid syndrome, prosthetic heart valves) according to the current Guidelines.
About the Authors
A. E. Bagry
Gorky Donetsk National Medical University of the Ministry of Health
Ukraine
MD, Prof.
Ukraine
MD, Prof.
O. A. Prikolota
Gorky Donetsk National Medical University of the Ministry of Health
Ukraine
PhD in medicine
Ukraine
PhD in medicine
E. V. Schukina
Gorky Donetsk National Medical University of the Ministry of Health
Ukraine
PhD in medicine
Ukraine
PhD in medicine
M. V. Khomenko
Gorky Donetsk National Medical University of the Ministry of Health
Ukraine
PhD in medicine
Ukraine
PhD in medicine
E. E. Kovyrshina
Donetsk Regional In-Patient Medical Association of the Ministry of Health
Ukraine
PhD in medicine
Ukraine
PhD in medicine
References
1. Stryuk RI. Anticoagulant therapy in pregnant women with mechanical prostheses of the heart valves. Meditsinsky Alfavit, 2013, 1 (4): 16-20
2. Alshawabkeh L, Economy KE, Valente AM. Anticoagulation during pregnancy. Evolving Strategies with a focus on mechanical valves. J Am Coll Cardiol, 2016, 68(16): 1804-1813.
3. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9thed: Americam College of Chest Physicians Evidence-Based Clinical Practice Guidelenes. Chest, 2012, 141(2): e691S-e736S.
4. Regitz- Zagrosek V, Blomstrom LС, Borghi С, Cifkova R, Ferreira R, Foidart JM et al. ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J, 2011, 32(24): 3147-3197.
5. De Santo LS, Romano G, Della Corte А, D’Oria V, Nappi G, Giordano S et al. Mechanical aortic valve replacement in young women planning on pregnancy: maternal and fetal outcomes under low oral anticoagulation, a pilot observational study on a comprehensive pre-operative counseling protocol. J Am Coll Cardiol, 2012, 59(12): 1110-1115.
6. Trofimov EA, Trofimova AS. Antiphospholipid syndrome: the progress of a disease in pregnant women and treatment options. RMJ, 2016, 15: 1032-1036
7. Reshetnyak Т.М. Antiphospholipid syndrome: diagnosis and clinical manifestations. Nauchno-Prakticheskaya Revmatologiya, 2014, 52 (1): 56-71
8. Baumgartner Н, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. ESC/EACTS Guidelines for the management of valvular heart disease/ The Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2017, 38(36): 2739-2791.
9. Dhir V, Pinto B. Antiphospholipid syndrome. J Mahatma Gandhi Inst Med Sci, 2014, 19: 19-27.
10. Clinical Practice Guideline: The diagnosis and management of severe pre-eclampsia and eclampsia/ Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Strategy and Programmes Division, Health Service Executive. Dublin, 2016, 22 р.
11. Prevention of venous thromboembolic complications in obstetrics and gynecology. Clinical recommendations (Protocol) (Letter of the Ministry of Health of the Russian Federation No. 15-4/10/2-3792 of May 27, 2014), Moscow, 2014, 32 p.
12. Khamashta М, Taraborelli М, Sciascia S, Tincani А. Antiphospholipid syndrome. Best Practice Res Clin Rheumatol, 2016, 30(1): 133-148.
13. Chaika VK. Fundamentals of reproductive medicine: a practical guide. Donetsk: PE Lavis, 2011. 896 p.
14. De Santis М, De Luca С, Mappa I, Cesari E, Mazza A, Quattrocchi T et al. Clopidogrel treatment during pregnancy: a case report and a review of literature. Intern Med, 2011, 50(16): 1769-1773.
15. Makatsariya AD, Bitsadze VO, Akinshina SV. Thromboembolic complications during pregnancy and low molecular weight heparin. Effektivnaya Farmakoterapiya. Akusherstvo i Ginekologiya, 2009, 1: 30-43
16. Saeed CR, Frank JB, Pravin М, Aziz RH, Serasheini M, Dominique TG. A pros pective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. Clin Appl Thromb Hemost, 2011, 17(4): 313-319.
17. Yarrington C.D., Valente A.M., Economy K.E. Cardiovascular management in pregnancy: antithrombotic agents and antiplatelet agents. Circulation, 2015,132:1354-1364.
18. Goland S, Schwartzenberg S, Fan J, Kozak N, Khatri N, Elkayam U. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels? J Cardiovasc Pharmacol Ther, 2014, 19(5): 451-456.
19. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux – data on efficacy and safety in special situations. Thromb Res, 2012, 129(4): 407-417.
20. Vavilova ТV. Anticoagulants in clinical practice. Place of antagonists of vitamin K on the background of new oral anticoagulants. Meditsinskiy Sovet, 2015, 12: 44-47
21. Hoeltzenbein М, Beck Е, Meixner К, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol, 2016, 105(2): 117-126.
22. Satybaldieva MA, Reshetnyak ТМ. New oral anticoagulants in the therapy of antiphospho-lipid syndrome. Nauchno-Prakticheskaya Revmatologiya, 2016, 54 (2): 219-226.
23. Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. USA Federal Register, 2014, 79(233): 72063-72103.
24. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. Flebologiya (annex), 2015, 9(2): 52 p.
25. Seredavkina NV, Reshetnyak ТМ. The 19th European Forum on Antiphospholipid Antibodies. Short review. Nauchno-Prakticheskaya Revmatologiya, 2014, 52 (1): 115-121
26. Gomes-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmunity, 2014, 48-49: 21-25.
27. Myers B, Pavord S. Diagnosis and management of antiphospholipid syndrome in pregnancy. J Obstet Gynaecol, 2011, 13: 15-21.
28. Khizroeva DKh, Bitsadze VO, Makatsaria AD, Stulyova NS. Catastrophic antiphospholipid syndrom during pregnancy. Akusherstvo i ginekologiya, 2017, 7, 155-160.
29. Turlupova TI, Artemenko KV, Gelyakhova ZA. Some issues of management of pregnancy in deep vein thrombosis of the lower extremities. Fundamental’nye Issledovaniya, 2008, 1: 40-44
30. Tepper NK, Boulet SL, Whiteman M.K, Monsour M, Marchbanks PA, Hooper WC et al. Postpartum venous thromboembolism: incidence and risk factors. Obstet Gynecol, 2014, 123(5): 987-996.
31. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin III JP, Guyton RA et al. AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echo-cardio graphy, Society for Cardiovascular Angiography and Inter ventions, Society of Cardio vascular Anesthesio logists, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2014, 63(22): 57-185.
32. Van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H et al. Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). ROPAC Investigators and the EURObservational Research Programme (EORP) Team. Circulation, 2015, 132(2): 132-142.
33. Nishimura RA, Otto CM, Bonow RO et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017. DOI: 10.1161/CIR.0000000000000503.
Review
For citations:
Bagry AE, Prikolota OA, Schukina EV, Khomenko MV, Kovyrshina EE. Use of antithrobomic agents in pregnancy and lactation: from the viewpoint of the cardiologist/rheumatologist (literature review). Meditsinskiy sovet = Medical Council. 2018;(6):19-25. (In Russ.) https://doi.org/10.21518/2079-701X-2018-6-19-25
Views:
1347
Email this article 